🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
46.84
+0.66 (1.43%)
Nov 20, 2026, 9:59 AM EST - Market open
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

Positive NT2, idiopathic hypersomnia and ADHD data advanced orexin programs, with multiple readouts planned over the next 12 months. Development is also exploring cognition, MDD and fatigue, while Phase III studies refine dosing and monitor safety.

Moderator

Okay, cool. Good afternoon, everyone. Day three of our Jefferies London Healthcare Conference. Tail end of the day, we are going to make it through. My name is Akash Tewari. I am a Pharma and Biotech Analyst here at Jefferies, and I have the pleasure of hosting the Alkermes management team and Blair. Alkermes is one of our top picks in mid-cap biotech, largely based on our growing confidence that orexin agonists are going to be backbone treatments for different types of hypersomnolence indications and potentially even more, and I am sure we are going to talk about that today. Blair, why do I hand it off to you for some intro questions, and we will go.

Blair Jackson
CEO, Alkermes

Great. Well, thanks for having me here. It is great to see you again. We are coming off a pretty transformational time for the company. This last year, we had a number of data readouts that have kind of moved us into the new space. We had the NT2 data with our ALKS 2680 program, very positive, moving us into phase III. We had positive results on LUMRYZ for idiopathic hypersomnia, which is moving us forward on registration. Then just a few weeks ago, we announced some positive ADHD data on our ALKS 7290 program, another orexin agonist that we have entered into the clinic. So, there is a lot been happening with the company, and as we move over into the next 12 months, from now until the end of next year, we probably have about six trials or so reading out over the course of that time.

We have our idiopathic hypersomnia study at the end of the year, three phase III programs, NT1, NT2, reading out in the middle of the summer. That is followed by our ADHD phase II dose-ranging study in the early fall, and then fatigue in ALKS 4510 right after that. So, a lot of catalysts for the company, a lot of growth. We are pretty excited to how this portfolio is starting to shape up.

Moderator

Understood. Now, it is interesting. I feel like you guys try to I remember talking to you and Richard in the summer, and even going before, you try to be humble in terms of where you think orexins are going. You are like, "Look, if Lilly wants to go into this area or that, interesting, but we are really focused on this." But the range of things that your team is looking at for orexins and where you feel like there is a good capital return has really widened beyond just NT1, NT2, and IH to now MDD and ADHD, right? But I know, Blair, you are very, very focused on making sure these are prudent investments, and you are really thinking about return on capital.

How does ADHD and MDD, what have we seen maybe from the orexin class in NT1, NT2, IH helped you feel more comfortable that going into these other indications makes sense?

Blair Jackson
CEO, Alkermes

Yeah. It's really interesting. I think as you look at moving outside diseases of hypersomnolence, there's a lot of interesting places that you can take these molecules. We really view this from a first principles perspective. We did a lot of work on neurotransmitter release. We did a lot of work on basic pharmacology to really understand how can you take these into new areas, where are you going to have the most translational outcome? What's similar to wakefulness that you could apply in a broader neuroscience indication? Things like ADHD and MDD fall right in that category. For example, we see in MDD, for example, that we can get a really strong synergistic effect in serotonin release in the prefrontal cortex and other areas of the brain synergistically when you give SSRIs and SNRIs.

That's a really interesting finding, which means we're actually going after the root cause of depression, not trying to treat sleep to get at depression, if you know what I mean. I think the same is true for ADHD. We were looking very carefully at acetylcholine release. We were looking at a lot of behavioral models in animals. These things make a lot of sense as you look at applying this methodology into other areas of neuroscience. That's kind of our philosophy of what's going to give us the best return, but also has a very strong probability of success.

Moderator

Understood. Now, it's interesting. If you look at some of the FDA review documents, the Japanese review documents, Takeda actually was in pretty in-depth discussions with the agencies about getting a cognition benefit for their orexin in Type 1. It goes directly to your point, where I think people think, "All right. Well, this is going to make you feel more awake. That's why you're going to have a benefit in certain subscales." It does seem like there's a element of cognition improvement that's distinct from simply wakefulness improvement. I know your team has a view on this as well. What have you learned looking at some of the FDA's interactions with Takeda, but then also some of the data you have in-house?

Blair Jackson
CEO, Alkermes

Well, I think we've seen across our programs that these mechanisms have cognitive benefit. In fact, when we look at our existing programs, our narcolepsy Type 1 study, our narcolepsy Type 2 study, we included direct cognition measurements as part of those studies. We were able to show very clearly that you could take patients from moderate and severe levels of cognitive deficit to normal. We see it consistently across the programs and in a dose-responsive way. Both us as well as Takeda have recognized this in our programs, and both of us have had interactions with the FDA about how do you approach this? Do you apply this? Does it show up in your clinical table? Do you actually get a separate claim for that? I think more clinical work would be needed there to demonstrate that.

We definitely feel that this is not being sleep-specific, that in fact you are getting a separate cognitive benefit outside of just sleep. That also applies to fatigue as well. We did exactly the same thing with fatigue in our NT1 and NT2 studies. We put the PROMIS fatigue scale in each of those studies and saw similar outcomes to what we saw with cognition.

Moderator

Understood. Now, I think one of the more under-discussed data sets, but probably quite important in this space, was the maintenance data that your team showed earlier this year in Type 1, but also Type 2 narcolepsy. What kind of really stood out to me was, A, that patients chose to get on higher doses because they felt increasingly probably comfortable with the safety profile. Then B, there was actually a deepening of response, not just on MWT, where I think there's been a lot of focus on, but on multiple different assessments. What did you learn from that maintenance data that you can apply to your development program outside of hypersomnolence indications?

Blair Jackson
CEO, Alkermes

Well, I think your point is really well taken that as you look at some of these new mechanisms, understanding the depth and duration of effect is really interesting. You have to pick an arbitrarily endpoint when you run these studies. It could be four weeks, six weeks, eight weeks, whatever. What we see is that with prolonged use, you're getting continued improvement. We also find, and you saw this in our NT2 study, that patients may have a preferred dosing lane. It may be you're randomized in the randomized trial to a dose that's not optimal for you, but when you optimize that dose for a patient, they get a continued benefit moving forward.

We see that in some of our programs as we think of ADHD, as we think of MDD, trying to understand how the effect size evolves over time is actually going to be an important element of our studies.

Moderator

Understood. Now, you have an idiopathic hypersomnia study reading out either end of year or next year. Sandy's looking at me, making it right. It's interesting, I talked to a lot of investors, they're like, "Oh, I love the 2027 setup for Alkermes. I'm just nervous into this IH data." I don't sense the same, let's say, nervousness from your team or that binary nature. Why is that the case? Why does your team Because I feel like your team's getting increasingly confident. We are going to be moving forward in IH. We just don't know exactly what that format's going to be.

Blair Jackson
CEO, Alkermes

Yeah, I mean, it's an interesting question. I think people, as you think about these indications, it's natural for people to want to segregate. Say you have an NT2 patient, NT1 patient, or an IH patient. What I think a lot of folks aren't realizing is that there's a lot of flow between these patient populations. The diagnosis between NT1 and NT2 is a little vague sometimes. Sometimes patients have cataplexy that's not recognized, but they're classified as an NT2, for example.

On the other end, we see a lot of movement of patients between an IH diagnosis and an NT2 diagnosis. As we think of the patient population that we're studying, we see it as being very similar to an NT2 population in the heterogeneity and how they respond to drug. They both have intact orexin tone, and so we would expect to see a similar effect size. We're using the same dosing, once-daily dosing, we're using the same doses. I think the main difference between the NT2 and the IH population is you do have a subgroup. You have a subgroup of long sleepers who are a little different phenotypically, but those long sleepers still experience excessive daytime sleepiness. That's still at rates similar to the NT2 group.

What we have seen with orexin agonism is that as you give super therapeutic levels of orexins, you can drive wakefulness. You can drive them in normals, you can drive them in NT2 population. So we would expect to see the long sleepers perform well as well. I think where people see the risk, I guess, is that we are pushing new boundaries here. This is the first time that an orexin agonist has been used in a broad IH population.

What we cannot do right now is just quantify that effect size. That is the purpose of this study. How do you design your phase III to have a statistical outcome that gets you a clinically meaningful outcome for patients?

Moderator

Understood. But I will say, you guys have still said, "Look, when we think about the type of signal we are looking at, 2 points to 3 points placebo-adjusted on ESS seems like a reasonable bar." Does that still hold true?

Blair Jackson
CEO, Alkermes

Yeah, I mean, that is a clinically meaningful movement on the scale. The unmet need in IH is tremendous. There is really one branded drug there, which is XYWAV right now.

Oxybates are great drugs, but they are not for everybody. I think an orexin agonist in the IH space is heavily needed. Remember, when we started our program, we started working in narcolepsy Type 1 and narcolepsy Type 2. We had some hesitation about IH because of IRA concerns and other things.

The patient community came to us. They were very clear. They are looking for medicines here. So, if you can show a clinically meaningful benefit in any way, they are more than happy to utilize your drug or to consider using your drug.

Moderator

Understood. Now, I remember when the NT2 data came out, and your team was having discussions. You talked about, "We are going to look at a BID formulation, and maybe that we get little better target coverage kind of in those last reads." I want you to kind of up to But one of the interesting things that I remember, you and Richard were mentioning is, we are seeing kind of two phenotypes. One group that would benefit from maybe BID dosing because we are seeing it in the curves and then it drops off, and then maybe another group where even if we dose more, we would not necessarily have a benefit. Do you still have that view that there is like maybe two distinct phenotypes now that you actually have maintenance data?

Right? That is really where it gets interesting. Can you talk a bit about that? Are there two different phenotypes in MWT, and then are there two different phenotypes in ESS? You still think that is the case here?

Blair Jackson
CEO, Alkermes

Well, I think as you look at the patient population here, within NT2, their sensitivity to orexin agonism can vary. I don't know whether it's two distinct populations or it's a spectrum of response.

Moderator

Right.

Blair Jackson
CEO, Alkermes

When you look at our OLE data, for example, you see more of a spectrum of response. You see a group of patients at different dose levels who perform differently, then in time, all normalize, which is great. I think the one thing, though, that we saw with the MWT test in our NT2 study is that that's a very sensitive test to specific time points in the course of a day. In a subset of patients, we saw that they were less responsive in the afternoon. We didn't see that in the total population.

That group would benefit best from a split dose. That was actually the impetus of us putting split dosing across our programs.

Moderator

Have you looked at split dosing in a maintenance setting yet?

Blair Jackson
CEO, Alkermes

This will be the first result that we will see with split dose performance in a clinical study, and I think that is part of why people are very interested in this data set.

Moderator

Understood. Now, I guess maybe going into phase III, one of the things that your team has hinted at is, look, the dose range that we explored here may not be actually the doses we take into phase III, and we feel increasingly comfortable about the safety profile of these orexins. Can you talk about, especially in your maintenance studies, what you are seeing in terms of AEs that are actually longer-lasting versus those that are really just acute ones that you get as your body is tolerating the drugs, but then they wane away over time?

Blair Jackson
CEO, Alkermes

Yeah, it is a good question. I think what we have seen across our programs and other programs that other companies have run is there is an adaptation that happens as a patient goes onto the drug the first time, and you do get some things like insomnia, for example, as a patient adapts to the new drug. That is sort of your circadian rhythm adjusting to a new event. Sometimes you will see that with headache. We saw in our NT1 trial some visual disturbances that were associated with that early onset piece. Really, the only long-term type AEs that you typically see, it is really polyuria, which is a frequency of urination, and we tend to see it mainly mild to moderate. It tends to be persistent in those patients who have it, but it does not tend to bother them.

It does not lead to discontinuations, and we also see that in response forms on global impression and things like that from patients in studies. They love being on the therapy still. They like the benefits it is giving. It is not disruptive to their treatment.

Moderator

Understood. Then maybe thinking about phase III's and tweaks you can make and learnings you had, you mentioned maybe there's a titration scheme. How does titration, let's say, implemented within a phase III, help deal with the rate of overall AEs, and how fast would that titration actually be for some of your trials?

Blair Jackson
CEO, Alkermes

Yeah, so the only area where we think a titration like that could help is in your NT1 population. What we saw in particular in our NT1 trials is that if you took a patient, they all have zero orexin tone, and if you were to take them and put them on the highest dose right away, you would tend to see more of those early tolerance issues. What we've done for our phase III actually is we step them first through an active dose for a couple weeks, and then once they've been on the active dose for a couple weeks, if they've been randomized to the high, then they'll move to the high dose. What that does is give them a little bit of a ramp so they can acclimatize to the new drug. We were just moving them and pushing them too fast.

Moderator

Understood. Do you feel like that might actually lead to differentiated safety relative to some of the Takeda assets that we've seen in NT1?

Blair Jackson
CEO, Alkermes

It may. It's really hard to compare the different drugs, where we are in the dose curve, and how we're dosing once daily versus their split dose, et cetera. I think our goal in this trial was to maximize efficacy and try to minimize our AE profiles as much as possible. Too soon to say whether it'll differentiate on that end.

Moderator

Understood.

Blair Jackson
CEO, Alkermes

Yeah.

Moderator

Now, on ADHD, it is interesting, again, there is investor perception, then you talk to strategics as well, then we talk to you. It was not placebo. It does not sound like there was a placebo separation. You seem to be relatively unbothered with that. I think the biggest tell is that when we look at your phase II study, you had every potential, enrich patients with baseline sleepiness, enhance the trial powering. Your stat design, you have talked about efficacy in line with certain stimulants. You are powered really to deliver that in phase II. That is a very big internal versus external kind of contrast right now, I am sure you have felt that too with talking to people. What do you see when you have the data in-house that maybe we are missing externally right now?

Blair Jackson
CEO, Alkermes

Well, I think when people are looking at the data set in the phase I-B and they start talking about placebo comparison, they are trying to make a trial, it a trial that it was not. It never was. This was a safety trial where we are trying to look at patients within an inpatient setting over two weeks. By the end of the trial, we actually only had eight placebo patients on the study. What we have seen and makes us confident in the mechanism is in that phase I-B study, we had a number of different things that we put in there, number of different patient-reported outcomes, physician-reported outcomes. We put objective measures in. What we saw across those is we saw consistent response. We saw robust responses. It was consistent regardless of how it was measured.

We saw at our high dose, we saw a CGI-S change of two in a two-week period of time. That is a pretty profound change regardless of how you look at that. For setting the size though, to look at are you VYVANSE-level efficacy, you need that big phase II study. It has to be powered correctly. We have the dose ranging so that we can look at dose response. The purpose of the two studies is very different, in order to do the bigger study, you are literally looking at more of an outpatient setting. It is a four-week outpatient versus our phase I-B, which is a two-week inpatient. Two very, very different characteristics.

Moderator

Understood. Another trial you have coming up next year, I would argue probably flying under the radar, is your fatigue study, right? So an MS and Parkinson's disease study. Fatigue.

Blair Jackson
CEO, Alkermes

Yeah.

Moderator

You guys have an underlying biological hypothesis, then you are really curious what plays out in the clinic. So help us understand, why choose MS and Parkinson's as kind of your two initial fatigue indications, and what are kind of two different clinical development pathways that branch out of that result?

Blair Jackson
CEO, Alkermes

Well, I will start with the last question first, because when we looked at fatigue is one of those areas that when you look at a lot of neuroscience as a whole and a lot of neurogenic disease, you see fatigue really plaguing a lot of these patients. We were hearing clearly in some of these programs how disruptive it is to patients' lives. You can think of big indications, things like chronic fatigue and things like that. You can think of cancer treatment fatigue.

We picked Parkinson's disease fatigue and MS fatigue to start because what we want to try to do is characterize this disease a little more thoroughly. One of the things you tend to hear when people talk about fatigue, because they do not know what the etiology is, they tend to talk about central fatigue and peripheral fatigue. So central fatigue being this exhaustion that you feel mentally. MS patients tend to describe that as their primary fatigue. When you talk to Parkinson's patients, they tend to describe more of a peripheral fatigue, a muscular fatigue, this bone-tired muscles, and you almost could expect that if you think of the diseases, it is what they are experiencing that is different. So, they could be just describing the same disease in a different way.

We want to know how orexin agonism works in these two different types, then we also want to test their individual scales. So, the PROMIS fatigue scale, the MS fatigue scale, the PD fatigue scales, to sort of see which is the most sensitive and accurate to assess these. Then we can meet with the FDA to talk about what is our path forward to develop these, and then to go into broader markets thereafter. So, it is actually a data-rich study. It is going to tell us a lot, and it will really point to what it is going to take to take it not only in these indications, which are large, but into the bigger indications that are more broad.

Moderator

Hmm. Now, I can tell you it did not surprise me to see a company like Lilly that has a vested interest in Alzheimer's look at an orexin agonist as maybe an asset they wanted in their pipeline. You guys have alluded to this, but I would love to get your take as well, because I think there is a provocative argument that this could be an ARICEPT, right? It is something that actually, it is a cognitive enhancer, it is relatively tolerable, it could be used as an adjunct therapy. Companies that are trying to commercialize Alzheimer's. Do you see validity in that pathway of thinking? You do not necessarily have trials there right now.

But what would be the use of an orexin in an adjunct Alzheimer's setting?

Blair Jackson
CEO, Alkermes

No, it is a great question. I think if you look at a lot of the therapies for Alzheimer's right now, they are taking a very different approach to treatment. I think when you take something like amantadine that has had a lot of benefit in use, but you could really improve on that with something that is driving a central mechanism. Adjunctive therapy in Alzheimer's is definitely an interesting area, and we have identified a number of areas in neuroscience where you could use this. It comes with complications, as you can imagine.

Elderly population, there are things going on with the brain and the ability to do that. When we talk about probabilities of success and investment, some of the ones we have picked now are a little more proximal, but that is definitely somewhere you could take orexin agonism.

Moderator

Understood. I think there's been It's funny, I've never seen more people bring just a calculator. They're like, "Here's the prevalence, here's a number, and then here's your peak sales." You'll see that sometimes when we talk about pancreatic cancer, but I'm sure you've heard a similar kind of way of thinking when you think about narcolepsy and pricing expectations. Takeda came out, and they came at a premium to sodium oxybate, and every investor is like, "Well, Takeda, why did you do this? You could have priced more." Why do you think Takeda did choose to price their drug where they did? How does that allow them to actually get rapid access out of the gate? How does that change your pricing decisions when your drug gets into the market?

Blair Jackson
CEO, Alkermes

Well, look, I think as Takeda's coming out with their drug, [inaudible], they're building a new market, whole new mechanism that they're going to have to educate patients on, educate physicians on. They're working with the payers to work through that system. They also have a global business that they're putting in place, and they have a lot of considerations that they're looking at. By any measure, that's a high-priced medication.

I think if you look at diseases of hypersomnolence and just kind of the treated populations, you're in the $25 billion range for an addressable market. So, these are big markets. I think Takeda's balancing the best it can do with the business and how it wants to do and how it's assessed access. We'll be watching carefully to see how

Moderator

Yeah

Blair Jackson
CEO, Alkermes

see how that performs. Obviously, we have a lot of flexibility with our program, three different indications, multiple doses, single dose, split dose. So, there's a lot of flexibility on how we approach that in the future, and we'll see how things progress and go from there.

Moderator

Understood. Last question before we let you go. I was surprised, and actually, our team went to Asia and spoke with Takeda, and I think they also were surprised to see an LDL increase with TAK-861. It showed up, I don't think they had published on that previously. Have you looked at impact of orexin? Do you think that's maybe an on-target effect or maybe something related to an individual scaffold?

Blair Jackson
CEO, Alkermes

I mean, I think it's something we haven't seen in our program, so I'm not sure it's necessarily an on-target effect. We do know, for example, that there's an interplay between sort of weight and lipids as patients go through their disease state. So, when we wash people out of their existing drugs, for example-

they'll eat excessively to stay awake. So, you'll see challenges there. So, I don't know whether it's a function of disease shining through or whether it's something different. But again, not something we've seen in our program to date. But we'll look for it in our phase III's.

Moderator

Understood. Wonderful conversation. I really did enjoy it. Thanks so much.

Blair Jackson
CEO, Alkermes

Okay. Thanks, Kash.